Short-Chain Fatty Acids (SCFAs)
Research reviewed: Up until 03/2026
Short-Chain Fatty Acids (SCFAs) (Acetate, propionate, butyrate) is a dietary supplement with 8 published peer-reviewed studies involving 282 participants, researched for Gut Barrier & Inflammation, Metabolic Health, Immune Regulation and 1 more areas.
Evidence at a Glance
Strength is scored by study design, sample size, study type, and outcomes
Gut Barrier & Inflammation
StrongMetabolic Health
ModerateImmune Regulation
ModerateNeurological & Gut Health
ModerateResearch Visualised
Visual breakdown of the clinical data.
Study Quality Breakdown
What types of studies were conducted
Participants Per Study
Larger samples = more reliable results
Research Timeline
When the studies were published
All Studies
Detailed breakdown of each trial. Click to expand.
Gut Barrier & Inflammation
To evaluate oral SCFA supplementation on gut barrier function and inflammation in ulcerative colitis.
Study Type
Randomised, double-blind, placebo-controlled
Purpose
To evaluate oral SCFA supplementation on gut barrier function and inflammation in ulcerative colitis.
Dose
Butyrate 4 g/day as enteric-coated tablets
Participants
48 patients with mild-moderate UC
Duration
8 weeks
Results
SCFA supplementation significantly reduced fecal calprotectin and improved intestinal permeability. Endoscopic improvement observed in 53% vs 28% placebo.
How They Measured It
Fecal calprotectin, intestinal permeability (lactulose/mannitol), endoscopic scores
To evaluate rectal SCFA enemas on distal ulcerative colitis.
Study Type
Randomised controlled trial
Purpose
To evaluate rectal SCFA enemas on distal ulcerative colitis.
Dose
SCFA mixture: acetate 60 mM, propionate 30 mM, butyrate 40 mM, 60 mL enema
Participants
47 patients with distal UC refractory to standard therapy
Duration
6 weeks
Results
SCFA enemas significantly improved Disease Activity Index, endoscopic appearance, and histological inflammation in refractory distal UC.
How They Measured It
Disease Activity Index, endoscopic score, histological inflammation
Metabolic Health
To evaluate colonic delivery of propionate on energy homeostasis and metabolic markers.
Study Type
Randomised, double-blind, crossover
Purpose
To evaluate colonic delivery of propionate on energy homeostasis and metabolic markers.
Dose
10 g/day inulin-propionate ester (delivering propionate to colon)
Participants
60 overweight adults
Duration
24 weeks
Results
Colonic propionate delivery significantly increased PYY and GLP-1, reduced energy intake, and prevented weight gain. Intra-abdominal fat distribution also improved.
How They Measured It
Body weight, adiposity (MRI), appetite hormones (PYY, GLP-1), insulin sensitivity
To assess the role of SCFAs in insulin sensitivity via colonic delivery.
Study Type
Randomised controlled trial
Purpose
To assess the role of SCFAs in insulin sensitivity via colonic delivery.
Dose
Acetate, propionate, or butyrate (various SCFA mixtures) via colonic catheter
Participants
12 normoglycemic overweight men
Duration
Acute single-dose infusions (3 visits)
Results
Colonic SCFA infusions significantly increased fat oxidation and energy expenditure. Acetate and butyrate increased fasting fat oxidation by 26%.
How They Measured It
Insulin sensitivity (hyperinsulinemic clamp), fat oxidation, energy expenditure
Immune Regulation
To evaluate SCFA supplementation on systemic inflammatory markers and immune cell function.
Study Type
Randomised, double-blind, placebo-controlled
Purpose
To evaluate SCFA supplementation on systemic inflammatory markers and immune cell function.
Dose
Sodium butyrate 600 mg/day
Participants
40 patients with metabolic syndrome
Duration
12 weeks
Results
Butyrate supplementation significantly reduced serum CRP and IL-6 levels. T-regulatory cell counts increased, suggesting enhanced immune regulation.
How They Measured It
Serum CRP, IL-6, TNF-alpha, T-regulatory cell counts
To evaluate propionate supplementation on immune regulation and Treg function.
Study Type
Clinical trial
Purpose
To evaluate propionate supplementation on immune regulation and Treg function.
Dose
500 mg sodium propionate twice daily
Participants
30 patients with multiple sclerosis
Duration
14 days
Results
Propionate significantly increased Treg cell frequency and FoxP3 expression. Anti-inflammatory cytokine profiles improved, suggesting immunomodulatory potential.
How They Measured It
Treg cell frequency, FoxP3 expression, inflammatory cytokines
To review the role of SCFAs in immune regulation and inflammatory disease.
Study Type
Systematic review
Purpose
To review the role of SCFAs in immune regulation and inflammatory disease.
Dose
Various
Participants
Review of 45 studies
Duration
Various
Results
SCFAs, particularly butyrate, modulate immune function through HDAC inhibition and GPR activation. Evidence supports roles in Treg induction, anti-inflammatory cytokine production, and gut barrier maintenance.
How They Measured It
Narrative synthesis of clinical and preclinical evidence
Neurological & Gut Health
To evaluate SCFA supplementation combined with prebiotics on clinical outcome in Parkinson's disease.
Study Type
Randomized, Double-Blind Prospective Study
Purpose
To evaluate SCFA supplementation combined with prebiotics on clinical outcome in Parkinson's disease.
Dose
Short-chain fatty acids (propionate, butyrate, acetate) plus prebiotic fiber
Participants
Parkinson's disease patients
Duration
12 weeks
Results
SCFA plus prebiotic supplementation significantly improved motor and non-motor outcomes in Parkinson's disease, with gut microbiome benefits.
How They Measured It
UPDRS motor scores, non-motor symptoms (constipation, mood), gut microbiome, fecal SCFA levels
Frequently Asked Questions
Common questions about Short-Chain Fatty Acids (SCFAs) research
There are currently 8 peer-reviewed studies on Short-Chain Fatty Acids (SCFAs) (Acetate, propionate, butyrate), involving 282 total participants. Research covers Gut barrier function, Anti-inflammatory, Metabolic health and 1 more areas. The overall evidence strength is rated as Strong.
The evidence is currently rated as "Strong Evidence". This rating is based on study design quality (randomisation, blinding, placebo controls), sample sizes, study types (7 human studies), and reported outcomes.
Short-Chain Fatty Acids (SCFAs) has been researched for: Gut barrier function, Anti-inflammatory, Metabolic health, Immune regulation. Each area has its own body of evidence which you can explore in the study breakdowns above.
Yes, 7 out of 8 studies are human trials. Human trials carry more weight in our evidence scoring system.
Similar Supplements
Other supplements researched for similar health goals
